Endothelial Cell Response to Combined Photon or Proton Irradiation with Doxorubicin.
additive effects
cell survival
combined treatment
doxorubicin
endothelial cells
migration
proliferation
proton beam radiotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
30
06
2023
revised:
31
07
2023
accepted:
01
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Surgery, radiotherapy, and chemotherapy are essential treatment modalities to target cancer cells, but they frequently cause damage to the normal tissue, potentially leading to side effects. As proton beam radiotherapy (PBT) can precisely spare normal tissue, this therapeutic option is of increasing importance regarding (neo-)adjuvant and definitive anti-cancer therapies. Akin to photon-based radiotherapy, PBT is often combined with systemic treatment, such as doxorubicin (Dox). This study compares the cellular response of human microvascular endothelial cells (HMEC-1) following irradiation with photons (X) or protons (H) alone and also in combination with different sequences of Dox. The cellular survival, cell cycle, apoptosis, proliferation, viability, morphology, and migration were all investigated. Dox monotreatment had minor effects on all endpoints. Both radiation qualities alone and in combination with longer Dox schedules significantly reduced clonogenic survival and proliferation, increased the apoptotic cell fraction, induced a longer G2/M cell cycle arrest, and altered the cell morphology towards endothelial-to-mesenchymal-transition (EndoMT) processes. Radiation quality effects were seen for metabolic viability, proliferation, and motility of HMEC-1 cells. Additive effects were found for longer Dox schedules. Overall, similar effects were found for H/H-Dox and X/X-Dox. Significant alterations between the radiation qualities indicate different but not worse endothelial cell damage by H/H-Dox.
Identifiants
pubmed: 37629014
pii: ijms241612833
doi: 10.3390/ijms241612833
pmc: PMC10454477
pii:
doi:
Substances chimiques
Protons
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Res. 2007 Feb 15;67(4):1803-11
pubmed: 17308123
Biomed Pharmacother. 2023 Jun;162:114576
pubmed: 36989721
Int J Mol Sci. 2019 Jun 29;20(13):
pubmed: 31261963
Mol Carcinog. 2022 Feb;61(2):165-172
pubmed: 34644811
J Natl Cancer Inst. 1996 Jun 5;88(11):699-700
pubmed: 8637018
Eur J Cancer. 2013 Jan;49(1):245-53
pubmed: 22683167
Br J Radiol. 2020 Mar;93(1107):20190601
pubmed: 31529979
Signal Transduct Target Ther. 2020 May 1;5(1):60
pubmed: 32355263
Front Cardiovasc Med. 2021 Mar 30;8:652761
pubmed: 33860001
Radiother Oncol. 2018 Jul;128(1):56-67
pubmed: 29861141
Front Physiol. 2019 Dec 18;10:1523
pubmed: 31920721
Radiat Res. 2012 Jul;178(1):33-45
pubmed: 22702646
Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1553-62
pubmed: 17920784
Redox Biol. 2021 Oct;46:102120
pubmed: 34479089
Cells. 2022 Jan 08;11(2):
pubmed: 35053325
Cancer Lett. 2019 Aug 10;457:1-9
pubmed: 31078733
Cancers (Basel). 2022 Apr 15;14(8):
pubmed: 35454915
Nat Chem. 2021 Aug;13(8):805-810
pubmed: 34112990
Radiother Oncol. 2021 May;158:21-32
pubmed: 33581220
Eur J Cancer. 2019 Mar;109:51-60
pubmed: 30690293
Nat Protoc. 2006;1(3):1458-61
pubmed: 17406435
Pharmacogenet Genomics. 2011 Jul;21(7):440-6
pubmed: 21048526
Sci Transl Med. 2015 Mar 11;7(278):278ra34
pubmed: 25761890
Front Oncol. 2018 Sep 10;8:367
pubmed: 30250827
Angiogenesis. 2018 Aug;21(3):425-532
pubmed: 29766399
J Pharm Biomed Anal. 2020 Jun 5;185:113231
pubmed: 32163849
Oncogenesis. 2015 May 18;4:e148
pubmed: 25985209
Arch Pharm Res. 2008 Jun;31(6):779-85
pubmed: 18563361
Front Oncol. 2023 Jul 12;13:1211984
pubmed: 37503316
Methods Mol Biol. 2018;1709:107-127
pubmed: 29177655
Radiat Oncol. 2022 Sep 14;17(1):159
pubmed: 36104789
J Invest Dermatol. 1992 Dec;99(6):683-90
pubmed: 1361507